Edward Holland, MD
Ophthalmology · Edgewood, KYNPI 1720021199
Payments from drug & device makers
Across 397 payments — averaging $3609.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$393K
- Kala Pharmaceuticals, Inc.$199K
- Sight Sciences, Inc.$165K
- Alcon$159K
- Johnson & Johnson Surgical Vision, Inc.$124K
- Novartis$111K
- plus $282K from 23 others
What the payments were for
- Consulting fees$465,97669%
- Speaking & faculty fees$58,6209%
- Grants$12,0002%
- Travel & lodging$9230%
- Food & beverage$6,9301%
- Other$133,39220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $392,697 |
| Kala Pharmaceuticals, Inc. | 71 | $199,055 |
| Sight Sciences, Inc. | 31 | $165,269 |
| Alcon | 37 | $159,163 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $123,553 |
| Novartis | 46 | $111,494 |
| Glaukos Corporation | 19 | $84,805 |
| Aerie Pharmaceuticals, Inc. | 13 | $40,096 |
| Alcon Research LLC | 27 | $39,152 |
| Bausch Health US, LLC | 12 | $36,750 |
| Oyster Point Pharma, Inc. | 13 | $32,424 |
| Dompe US, Inc. | 14 | $21,762 |
| Carl Zeiss Meditec, Inc. | 10 | $9,889 |
| Ocular Therapeutix, Inc. | 3 | $5,269 |
| Merck Kgaa | 3 | $4,270 |
| Shire North American Group Inc | 5 | $2,082 |
| Dompe Farmaceutici S.p.a. | 2 | $1,318 |
| Eyevance Pharmaceuticals LLC | 3 | $1,034 |
| Eyepoint US, Inc. | 9 | $1,017 |
| Tearlab Corp | 2 | $547 |
| Harrow Eye, LLC | 5 | $407 |
| Tarsus Pharmaceuticals, Inc. | 4 | $247 |
| Bausch & Lomb Americas Inc. | 7 | $131 |
| Biotissue Holdings Inc. | 4 | $128 |
| Sun Pharmaceutical Industries Inc. | 5 | $79 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Alimera Sciences, Inc. | 3 | $58 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $51 |
| Coherus Oncology, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$145,028
- iStent Trabecular Micro-Bypass Stent System$50,162
- iStent inject Trabecular Micro-Bypass Stent System$45,162
- MEIBOMIAN GLAND EVALUATOR$45,000
- XIIDRA$22,670
- iStent inject W$20,148
- iStent$20,000
- ILUX$14,000
- CALLISTO eye$7,500
- TearCare SmartLid$6,938
- TEARCARE(TM) (2.2) SYSTEM KIT$6,938
- Oxervate$6,500
- Centurion$5,775
- ARGOS$5,600
- IOLMaster$5,500
- DEXTENZA$5,200
- DUREZOL$5,040
- DAILIES$4,900
- TearCare$4,391
- CIRRUS HD-OCT$4,000
How this compares
$1,432,823 in reported general payments places this provider in the 95th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 28 | $1,122,183 |
| RestasisCyclosporine | 174 | $143,269 |
| Loteprednol Etabonate | 208 | $35,613 |
| Difluprednate | 261 | $34,122 |
| XiidraLifitegrast | 42 | $31,535 |
| Prednisolone Acetate | 741 | $27,466 |
| Cyclosporine | 68 | $23,145 |
| MoxifloxacinMoxifloxacin Hcl | 491 | $17,510 |
| Tacrolimus | 151 | $17,306 |
| IlevroNepafenac | 43 | $15,680 |
| Mycophenolate Mofetil | 226 | $14,938 |
| InveltysLoteprednol Etabonate | 25 | $12,863 |
| TyrvayaVarenicline Tartrate | 13 | $9,799 |
| Lotemax SmLoteprednol Etabonate | 25 | $9,503 |
| ValacyclovirValacyclovir Hcl | 172 | $9,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $21,762 | $1,122,18328 claims |
| AbbVieRestasis, Combigan | $392,697 | $147,142186 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Prolensa | $51 | $51,254251 claims |
| Bausch & Lomb Americas Inc.Xiidra | $131 | $31,53542 claims |
| NovartisIlevro | $111,494 | $15,68043 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $199,055 | $12,86325 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $32,424 | $9,79913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Edgewood
- Guruprasad PattarLouisville$934K
- Brennan GreeneLouisville$688K
- Johnathon DowningBowling Green$649K
- John MeyerLouisville$587K
- Mohammad HaiderLouisville$498K
- Gary WortzLexington$159K
- Jeffery TaylorPaducah$137K
- Jeremy ClarkLouisville$131K
- Victor NeamtuLouisville$105K
- Asim PirachaLexington$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.